

1 **Standardized Data Elements for Patients with Acute Pulmonary Embolism**

2
3 A Consensus Report from the Pulmonary Embolism Research Collaborative

4
5 Kenneth Rosenfield, MD, MSc, Terry R. Bowers, MD², Christopher F. Barnett, MD, MPH³,
6 George A. Davis, PharmD, BCPS⁴, Jay Giri, MD, MPH⁵, James M. Horowitz, MD⁶, Menno V.
7 Huisman, MD, PhD⁷, FESC⁷, Beverley J. Hunt OBE, MD⁸, Brent Keeling, MD, Jeffrey A. Kline,
8 MD⁹, Frederikus A. Klok, MD, PhD⁷, Stavros V. Konstantinides, MD¹⁰, Michelle T Lanno¹⁴,
9 Robert Lookstein, MD, MHC DL¹¹, John M. Moriarty, MD¹², Fionnuala Ní Áinle, MD, PhD¹³,
10 Jamie L. Reed, MS¹⁴, Rachel P. Rosovsky, MD, MPH¹⁵, Sara M. Royce PhD¹⁶, Eric A.
11 Secemsky, MD, MSc¹⁷, Andrew SP Sharp, MD¹⁸, Akhilesh K. Sista, MD¹⁹, Roy E. Smith, MD,
12 MS²⁰, Phil Wells, MD, MSc²¹ Joanna Yang, BA¹⁵, Eleni M. Whatley, PhD¹⁶

13
14 *On behalf of attendees at the inaugural PERC™ meeting held in Washington DC on April 22,*
15 *2022 (See Appendix 2 for full listing)*

16 17 **AFFILIATIONS**

18
19 ¹Division of Cardiology, Massachusetts General Hospital, Boston, MA Massachusetts

20 ²Corewell Health, Beaumont University Hospital, Division of Cardiovascular Medicine, Royal Oak, MI

21 ³Division of Cardiology, University of California, San Francisco, CA

22 ⁴University of Kentucky UK HealthCare; University of Kentucky College of Pharmacy, Lexington, KY

23 ⁵Cardiovascular Medicine Division, University of Pennsylvania Perelman School of Medicine

24 ⁶NYU Langone Health, Department of Medicine, Division of Cardiology, New York, NY

25 ⁷Department of Medicine - Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, the Netherlands
26 and Dutch Thrombosis Network

27 ⁸Kings Healthcare Partners, London UK

28 ⁹Wayne State University School of Medicine, Detroit, MI

29 ¹⁰Center for Thrombosis and Hemostasis, University Medical Center Mainz, Germany; Department of Cardiology,
30 Democritus University of Thrace, Greece

31 ¹¹Icahn School of Medicine at Mount Sinai; New York, NY

32 ¹²David Geffen School of Medicine at UCLA, Los Angeles, CA

33 ¹³University College Dublin School of Medicine, Mater Misericordiae University Hospital, Dublin, Ireland, Royal
34 College of Surgeons in Ireland

35 ¹⁴The PERT Consortium™, Nashua, NH

36 ¹⁵Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA

37 ¹⁶US Food and Drug Administration, Silver Spring, MD

38 ¹⁷ Beth Israel Deaconess Medical Center, Boston, MA

39 ¹⁸University Hospital of Wales and Cardiff University

40 ¹⁹Weill Cornell Medicine, Department of Radiology, New York, NY

41 ²⁰ Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA

42 ²¹Department of Medicine, The Ottawa Hospital; University of Ottawa, Ottawa, ON

43

44 **CORRESPONDING AUTHOR**

45 Kenneth Rosenfield, MD, MSc

46 Krosenfield1@mgh.harvard.edu

47 krosenfield@fastmail.us

48 55 Fruit Street

49 Boston, MA 02114

50

51 **Word Count: 4767**

52 **Disclaimer** — This article reflects the consensus views of the writing group and does not necessarily represent the
53 practices, policies, requirements or recommendations of the FDA. Further, the use of the word “required”, “must” or
54 “should” in the document is not intended to indicate an FDA requirement.

55

56 **Disclosures**

57 Dr. Rosenfield reports consult fees from Abbott Vascular, Angiodynamics, Inc., Auxetics,
58 Becton-Dickinson, Boston Scientific, Inc., Contego, Imperative Care, Johnson & Johnson,
59 Biosense Webster, Medtronic, Neptune Medical, Philips, Surmodics, and Terumo, Board
60 Member for The PERT Consortium™, and stock or stock options in Access Vascular, Aerami,
61 Althea Medical, Auxetics, Contego, Endospan, Imperative Care, Innova Vascular, InspireMD,
62 JanaCare, Magneto, MedAlliance, Neptune Medical, Orchestra, Prosomnus, Sealonix,
63 Shockwave, Skydance, Summa Therapeutics, Thrombolex, Valcare, Vantis Vascular, Vasorum,
64 and Vumedi.

65 Dr. Bowers reports consulting fees from Truvic, Inc., lecture fees from Janssen and BMS-Pfizer,
66 payment for expert testimony, participation on Advisory Board of Truvic, Inc.

67 Dr. Barnett reports payment for expert testimony.

68 Dr. Davis reports travel support for attending the Pulmonary Embolism Research Collaborative
69 meeting.

70 Dr. Giri reports research support from Boston Scientific, Inc. and Inari Medical, consulting fees
71 from Boston Scientific, Inc., Cordis, and Abbott Vascular, support for attending meetings from
72 Inari Medical, participation on an Advisory Board for Angiodynamics, Inc. and Boston
73 Scientific, Inc., participation in leadership at SCAI and The PERT Consortium™, and stock or
74 stock options in Endovascular Engineering.

75 Dr. Horowitz reports research support from Inari Medical, consultation and personal lecture fees
76 from Inari Medical and Penumbra, Inc., and support for attending meetings from Inari Medical.

77 Professor Dr. Huisman reports no conflicts of interest.

78 Professor Dr. Hunt reports no conflicts of interest.

79 Dr. Keeling reports consulting fees from Angiodynamics, Inc., Penumbra, Inc., Viz.ai, and
80 Dexcom.

81 Dr. Kline reports no conflicts of interest.

82 Professor Dr. Klok reports institutional research support from Bayer, Bristol-Myers Squibb,
83 Actelion, Boston Scientific, Inc, Leo Pharma, The Netherlands Organisation for Health Research
84 and Development, The Dutch Thrombosis Association, The Dutch Heart Foundation, and the
85 Horizon Europe program, service on the Board of the Rembrandt Institute of Cardiovascular
86 Science, Chair of the Board of the Dutch Society of Vascular Medicine, nucleus member of the
87 ESC work group on pulmonary circulation and RV function, nucleus member of ISTH SSC
88 diagnostic and predictive variables, Chair of the Board of the Dutch Thrombosis Network, and
89 medical lead Anticoagulation Clinic Leiden.

90 Professor Dr. Konstantinides reports personal and institutional consulting fees from Bayer AG,
91 Daiichi-Sankyo, and Boston Scientific, Inc., and personal lecture fees from Bayer AG, Daiichi-
92 Sankyo, Pfizer – Bristol-Myers Squibb, and Boston Scientific, Inc.

93 Ms. Lanno reports no conflicts of interest.

94 Dr. Lookstein reports consulting fees from Penumbra, Inc., Boston Scientific, Inc., Medtronic,
95 Cordis, Becton Dickinson, Abbott Vascular, Neptune Medical, Imperative Care, and Aidoc,
96 payment for expert testimony, participation on Advisory Board for Magneto, Boston Scientific,
97 Inc., Medtronic, and Trireme, leadership roles at The PERT Consortium™, CLI Global Society,

98 and Society of Interventional Radiology, stock or stock options in Imperative Vascular,
99 Thrombolex, Innova Vascular, and Summa Vascular.

100 Dr. Moriarty reports research support from Angiodynamics, Inc. and Penumbra, Inc., consulting
101 fees from Angiodynamics, Inc, Penumbra Inc., Inquis Medical, Innova Vascular, Boston
102 Scientific Inc., Auxetics, and Retriever Medical, and participation on the data safety monitoring
103 board for Penumbra, Inc.

104 Professor Dr. Ní Áinle reports institutional research support from Sanofi, Daiichi-Sankyo, the
105 Irish Health Research Board, Bayer, and Boston Scientific, Inc., patents pending for European
106 Application No. 20166826.6, past member of World Thrombosis Day International Steering
107 Committee, Director at Large and Member, INVENT Council, Co-Director, InVite, Co-Founder
108 and member of Executive Committee of VTE Ireland, Advisory Committee for ACHM, Member
109 of “Preventing venous thromboembolism in hospitals” Collaborative Advisory Group, Board
110 Member, Thrombosis Ireland Patient Organization and Charity, and National Lead, Irish VTE
111 Patient Safety Programme.

112 Ms. Reed reports no conflicts of interest.

113 Dr. Rosovsky reports research support from BMS and Janssen, consulting fees from Abbott,
114 BMS, Dova, Inari Medical, Janssen, and Penumbra, Inc., participation on the data safety
115 monitoring board for the Pepper Trial and Harvard Cancer Center, unpaid President-Elect of the
116 PERT Consortium and unpaid member of ASH Committee on Quality.

117 Dr. Royce reports no conflicts of interest.

118 Dr. Secemsky reports research support from NIH/NHLBINIH/NHBLI K23HL150290, Food &
119 Drug Administration, BD, Boston Scientific, Inc., Cook Medical, CSI, Laminate Medical,
120 Medtronic, and Philip, consulting fees and personal lecture fees from Abbott, Bayer, BD, Boston
121 Scientific, Inc., Cook, CSI, Inari Medical, Medtronic, Philips, Shockwave, and VentureMed, ad
122 participation on data safety monitoring boards for LIFE BTK, BIOMIMCS3D, HI-PEITHO, and
123 Transcend.

124 Professor Dr. Sharp reports consulting and lecture fees from Medtronic, Boston Scientific, Inc.,
125 Philips, Recor Medical, and Penumbra, Inc.

126 Dr. Sista reports research support from NIH/NHLBI as principal investigator of U34 and UG3
127 awards, unpaid participation on data safety monitoring boards for Angiodynamics, Inc. and

128 Thrombolex, Inc., and participation on the Board of Directors for the Society of Interventional
129 Radiology.

130 Dr. Smith reports no conflicts of interest.

131 Dr. Wells reports participation on the data safety monitoring board for Anthos.

132 Ms. Yang reports no conflicts of interest.

133 Dr. Whatley reports no conflicts of interest.

134

135

136 **ABSTRACT**

137

138 Recent advances in therapy and the promulgation of multidisciplinary pulmonary embolism
139 teams (PERTs) show great promise to improve management and outcomes of acute pulmonary
140 embolism (PE). However, the absence of randomized evidence and lack of consensus leads to
141 tremendous variations in treatment and compromises the wide implementation of new
142 innovations. Moreover, the changing landscape of healthcare, where quality, cost, and
143 accountability are increasingly relevant, dictates that a broad spectrum of outcomes of care must
144 be routinely monitored to fully capture the impact of modern PE treatment. We set out to
145 standardize data collection in PE patients undergoing evaluation and treatment, and thus
146 establish the foundation for an expanding evidence base that will address gaps in evidence and
147 inform future care for acute PE. To do so, over 100 international PE thought leaders convened in
148 Washington, DC in April 2022 to form the Pulmonary Embolism Research Collaborative (
149 PERC™). Participants included physician experts, key members of the United States Food and
150 Drug Administration (FDA), patient representatives, and industry leaders. Recognizing the
151 multi-disciplinary nature of PE care, the Pulmonary Embolism Research Collaborative
152 (PERC™) was created with representative experts from stakeholder medical subspecialties,
153 including cardiology, pulmonology, vascular medicine, critical care, hematology, cardiac
154 surgery, emergency medicine, hospital medicine, and pharmacology. A list of critical evidence
155 gaps was composed with a matching comprehensive set of standardized data elements; these data
156 points will provide a foundation for productive research, knowledge enhancement, and
157 advancement of clinical care within the field of acute PE, and contribute to answering urgent
158 unmet needs in PE management. Evidence produced through PERC™, as it is applied to data
159 collection, promises to provide crucial knowledge that will ultimately produce a robust evidence
160 base that will lead to standardization and harmonization of PE management and improved
161 outcomes.

162

163 **CLINICAL PERSPECTIVE**

164

1) What is new?

165

- Recent advances have increased options for treatment of acute pulmonary embolism, yet there remain wide variations in management due to the lack of a reliable evidence base upon which to base therapeutic decisions.

166

167

- 168 • The PERT ConsortiumTM is a strong advocate of evidence based care for PE patients
169 and therefore initiated the Pulmonary Embolism Research Collaborative (PERCTM) to
170 establish a foundation for advancing high quality research and improving clinical
171 care.
- 172 • A novel comprehensive set of standardized data elements is proposed for collection in
173 patients with acute pulmonary embolism, to provide a foundation for expanding the
174 evidence base and enhancing care.
- 175 2) What are the clinical implications?
- 176 • Standardizing collection of data for acute pulmonary embolism will enable analyses
177 that will inform optimal risk stratification, treatment, and follow-up of patients with
178 pulmonary embolism, and provide evidence-based treatment algorithms that will
179 improve outcomes.
- 180 • Registries created using the proposed standardized elements will enable
181 benchmarking and quality assurance for clinicians caring for pulmonary embolism
182 patients.
- 183 • Incorporation of comprehensive standardized data elements into FDA IDE trials will
184 enable the Agency to better assess the safety and effectiveness of investigational
185 devices.
- 186

187 **ABBREVIATIONS**

188

189	AI	Artificial Intelligence
190	AC	Anticoagulation; Anticoagulant
191	CBT	Catheter-based Thrombectomy
192	CDL	Catheter-directed Thrombolysis
193	CDER	Center for Drug Evaluation and Research
194	CDRH	Center for Devices and Radiological Health
195	CPET	Cardiopulmonary Exercise Testing
196	CTEPD	Chronic Thromboembolic Pulmonary Disease (also referred to as CTED)
197	CTEPH	Chronic Thromboembolic Pulmonary Hypertension
198	ECMO	Extracorporeal Membrane Oxygenation
199	EMR	Electronic Medical Record
200	ESC	European Society of Cardiology
201	FDA	Food and Drug Administration
202	MCS	Mechanical Circulatory Support
203	PE	Pulmonary Embolism
204	PERC	Pulmonary Embolism Research Collaborative

205 **PERT** Pulmonary Embolism Response Team
206 **PRO** Patient Reported Outcome
207 **VTE** Venous Thromboembolism
208

209 INTRODUCTION

210 Acute pulmonary embolism (PE) is a major source of cardiovascular morbidity and
211 mortality and a leading cause of preventable in-hospital death in the US and around the world.¹⁻⁷
212 Despite its high prevalence, clinical impact, and considerable public health implications, there
213 remains a lack of consensus regarding what constitutes the optimal strategy for management of
214 acute PE. The significant variability in the application of newer treatment modalities highlights
215 the lack of consensus and need for standardization. Unlike myocardial infarction (MI) and
216 stroke, for which robust evidence has led to consistent and standardized treatment, the absence of
217 level I evidence regarding the management of PE has resulted in large variations in care. Further
218 exacerbating this variability is the fact that PE is managed by several different specialties, each
219 of which brings its own perspective and bias.

220 The most important reason for variability in treatment lies in the evidence gap that exists
221 regarding optimal risk stratification and related risk-based management strategies,
222 standardization of indication and application of interventional advanced PE treatment, and
223 widely-accepted measures regarding outcomes of care for PE. Recent advances in treatment and
224 availability of novel catheter directed techniques underscores the need for standardization of data
225 collection in routine care, which is essential to understand their impact.

226 A core set of outcome measures for venous thromboembolism (VTE) was recently
227 proposed by the International Consortium for Health Outcomes Measurement (ICHOM);
228 however this set does not include relevant data elements regarding risk stratification and details
229 of management decisions and is therefore insufficient to guide the much needed process of
230 harmonization and standardization of PE management.^{8, 9} The Pulmonary Embolism Research
231 Collaborative (PERCTM) was conceived as a forum to develop a pragmatic core set of data
232 elements, with common standards and definitions, that will serve as the foundation for data
233 collection regarding the evaluation, treatment, outcomes, and follow up. The evidence generated
234 by collecting such standardized data will enable analyses that will enhance clinical care, establish
235 quality metrics, and promote research endeavors.

236

237 METHODOLOGY

238 *PERCTM composition*

239 An international group of multidisciplinary experts in PE convened to work in
240 collaboration with the United States Food and Drug Administration (FDA), patient
241 representatives, healthcare organizations, and industry leaders, to explore gaps in recognition,
242 diagnosis, treatment, and follow up of patients with acute PE. (**Figure 1**) PERC™ healthcare
243 contributors represented the multidisciplinary character of PE care and included international
244 representative experts from stakeholder medical subspecialties and scientific societies, including
245 cardiology, pulmonology, vascular medicine, critical care, hematology, cardiac surgery,
246 emergency medicine, hospital medicine, and pharmacology. Physician thought leaders were
247 invited to participate based on their past contribution to PERT efforts as well as their
248 involvement in contemporary trials for PE. Individuals invited to participate in PERC each
249 obtained institutional approval to participate. FDA representatives received endorsement to
250 participate on behalf of the Agency.

251

252 *PERC™ objectives*

253 The three objectives of PERC were: 1) to identify the current major evidence gaps that
254 must be closed in order to better inform care providers and reduce variations in PE care; 2) to
255 identify what data capture will be necessary to close those gaps; and 3) to develop consensus
256 regarding a set of core set of data elements to be captured in routine care in all patients treated
257 for PE. Ultimately, this initiative was to generate a comprehensive compendium of data elements
258 pertaining to how patients are risk-stratified and treated, and to capture outcomes. Notably,
259 PERC™ was not intended to establish recommended algorithms or guidelines for care.
260 Ultimately, analyses derived from databases utilizing these standardized elements proposed by
261 PERC™ will: a) establish the relative value and utility of current risk stratification tools; b)
262 illuminate additional factors that may influence care and outcome, perhaps leading to creation of
263 new tools for prognostication; c) enable more standardized and balanced assessment of outcomes
264 using different therapeutic approaches; d) provide meaningful evidence to inform future
265 guidelines and care algorithms.

266

267 *PERC™ methodology and procedures*

268 Five working groups (**Figure 2**), based on timing relative to patient presentation and
269 intervention, were formulated before the meeting and leaders representing different disciplines

270 were selected for each. Groups were charged with developing consensus around a set of data
271 elements for capture pertaining to important knowledge gaps. In order to maximize productivity
272 at the on-site PERC™ meeting, groups were asked to prepare their respective work product in
273 advance. Accordingly, in the weeks leading up to the PERC™ meeting day, group leaders
274 convened a series of workgroup virtual meetings. During the meeting, these proposed gaps in
275 evidence and relevant data elements were discussed and finalized.

276

277 *Establishment of list of data elements*

278 Data elements throughout the entire “PE journey”, from presentation through discharge,
279 and into follow up were considered in order to assess the various management strategies,
280 decisions, and care rendered for acute PE, and the impact of these on outcomes. The timeline
281 was divided into 5 distinct serial “events” representing milestones in the journey (**Figure 2**).
282 Alternative (exploratory) elements not included in prior data collection efforts were considered,
283 which could ultimately be relevant and predictive or influence outcomes, and therefore be
284 important to capture. Elements were grouped into categories of “core” (i.e. absolutely necessary)
285 and “enhanced” (i.e. beneficial to know for research and exploratory purposes). There was
286 specific emphasis on identifying data elements that are pragmatic, such that they could be
287 captured according to consensus definitions and at appropriate time points, with good
288 ascertainment.

289 Practicable definitions that could be applied across institutions and easily understood by a
290 broad professional audience were applied when available. Consideration was given to whether it
291 was realistic to expect participating clinicians or institutions, during routine patient care, to
292 collect the data element in a standardized manner. Evidence derived from the existing medical
293 literature was used to justify final recommendations.

294

295 *Data sharing*

296 An important concept in collection of data regarding PE from a broad base, as is expected
297 in tools utilizing the PERC elements, is an agreement that data-sharing should be enabled to the
298 extent that is legally and ethically possible. As such, users who share the common elements and
299 definitions established by PERC will be encouraged to share de-identified data and thus enhance

300 the overall dataset, enabling large-scale analyses that will increase the evidence base surrounding
301 care of PE.

302

303 **RESULTS**

304 Discussion in the working groups and during the PERC™ meeting resulted in
305 concentration on focused topics, including the current gaps in evidence and the need for specific
306 data element capture.

307 *Gaps in Evidence*

308 After discussion in the working groups and during the PERC™ meeting, twelve crucial
309 gaps in evidence were established as being the most important drivers of current variations in PE
310 management and challenges that need to be overcome to improve the outcomes of care. (See
311 **Table 1**). The gaps in evidence shown in were the driver of the selection and definition of data
312 elements. An important unmet need addressed by the PERC™ experts was to clarify the roles of
313 patient education, shared decision-making, and patient reported outcomes (PRO) within
314 treatment paradigms.

315

316 *List of Data Elements*

317 During the PERC™ meeting, 351 data elements were identified and defined. The final list
318 of data elements listed fully in **Appendix 1** represent the ultimate output of the PERC™
319 meeting. For all data elements, the status (core versus enhanced) is indicated, as well as a
320 definition, relevant side notes (e.g. relevant metadata standards) and/or a supporting reference
321 where appropriate. The highlights of this list of data elements are detailed below.

322 The initial assessment includes common demographic parameters, risk factors and
323 clinical details. Demographic elements determined to be of particular importance include sex
324 assigned at birth (male, female, or other) and separate elements for race and ethnicity, based on
325 recommendations from the Office of Minority Health.¹⁰ Standards for collection of race and
326 ethnicity information are delineated on a prior document from the FDA entitled “Collection of
327 Race and Ethnicity Data in Clinical Trials”¹¹. Patient-level zip code is recommended as an
328 important potential covariate for socioeconomic characterization, as is insurance status. This
329 information is important to capture and evaluate, as health disparities in management of PE

330 hospitalizations and PE follow-up, based on race^{12, 13}, gender^{14, 15}, and socioeconomic status¹⁶
331 have been reported.

332 Presenting clinical symptoms include those routinely endorsed by the patient on initial
333 evaluation. Particular attention should be paid to the duration of PE symptoms (in days), as this
334 may have significant interactions with the risk/benefit profiles of various PE therapeutics. Vital
335 signs on admission and at various time points thereafter are relevant. Elements associated with
336 hemodynamic compromise (e.g. cardiac arrest, hypotension requiring vasopressors, need for
337 mechanical circulatory support) as well as respiratory compromise (e.g., requiring supplemental
338 oxygen or mechanical ventilation) are captured. The recommended elements will enable
339 calculations of various prognostic PE risk scores, including the sPESI score, Bova scores,
340 National Early Warning Score and others.¹⁷⁻²⁰ For that purpose, specific quantitative values of
341 key laboratory tests are to be captured. For the same reason, the data elements also include
342 details of initial imaging evaluations, including PE-protocol computed tomographic (CT)
343 imaging and transthoracic echocardiography, performed either by a trained ultrasonographic
344 technician/echocardiologist or as a point-of-care ultrasound (POCUS) by a physician or other
345 qualified provider. Data elements associated with an escalation of care therapy, resulting in an
346 (interventional) reperfusion procedure, should be captured, including all treatment pathways,
347 along with specific parameters for each selected treatment approach. For all patients, typical
348 procedural parameters, as well as baseline information that may inform the primary treatment
349 decision, should be considered. These include, among others, date and time of PERT activation,
350 the specialties involved in the team, and the presence of any known contraindication to
351 anticoagulation and/or thrombolysis. For catheter-based therapies, such as catheter-directed
352 thrombolysis (CDT) and catheter-based thrombectomy (CBT), complete device information,
353 including either the unique device identifier (UDI) or brand, model and size, is pertinent. The
354 exact location of treatment, access site information, and vascular closure information should be
355 collected. For CDT, the drug type, dose, administration strategy (i.e., bolus vs infusion), and
356 duration of treatment is essential. For CBT, whether the procedure entailed aspiration,
357 mechanical disruption, or a combination is important. All elements related to the exact device
358 type, treatment details, and drugs/dosages are considered core.

359 Procedure timing, specifically how to define the initiation of therapy and events related to
360 a therapeutic intervention, is an important consideration and must be captured in order to enable

361 accurate post-hoc analysis to evaluate and compare therapies. Given that specific data elements
362 are being recommended to be conducted at various time points, the “start time” needs to be
363 defined. This may be different for various therapies administered and, in the event that more than
364 one therapy is administered, separate start times should be documented for each, rather than the
365 whole “procedure.” For pharmaceutical treatments, including anticoagulation and systemic
366 thrombolysis, the initiation of therapy is defined as the time when the drug is administered. For
367 other device-based therapies, the initiation of therapy is defined as the time of venous access for
368 the intervention. Specific focus is not placed on “door to catheter time,” though this should be
369 calculable, as this has been reported that reduction of this time has a favorable impact on
370 outcomes²¹. End of therapy is also captured, defined as follows:

- 371 - Oral anticoagulation– After administration of the first oral agent
- 372 - Parenteral anticoagulation– After injection of the first agent
- 373 - Systemic Thrombolysis – After the infusion is discontinued
- 374 - Catheter-based thrombolysis – After the completion of the lytic infusion
- 375 - Catheter-based thrombectomy – After leaving the angiographic suite
- 376 - Surgical thrombectomy – After leaving the operating room

377
378 Definitions for acute clinical success, which may differ based on the hemodynamic status
379 of the patient, are summarized in **Table 2** and provide more detail to the definition of treatment
380 success as suggested by the European Society of Cardiology.²² It is recognized that not achieving
381 one or more of these definitions within 48 hours does not necessarily reflect that clinical
382 improvement will not or has not partially been achieved (i.e., stabilized patient on ECMO
383 support for >48 hours). However, to associate hemodynamic improvement with a therapeutic
384 intervention requires proximity to the procedure (within 48 hours, by consensus of the group). It
385 is recognized that not achieving one or more of these endpoints within 48 hours does not
386 necessarily reflect that clinical improvement will not or has not partially been achieved (i.e.,
387 stabilized patient on ECMO support for >48 hours). However, to associate hemodynamic
388 improvement with a therapeutic intervention requires proximity to the procedure (within 48
389 hours, by consensus of the group).

390 Definitions for treatment failure and treatment-associated complications were agreed
391 upon as well and illustrated in **Table 3**. Post-discharge management includes the collection of

392 specific data elements post-discharge, such as adverse events (e.g. recurrent venous
393 thromboembolism or bleeding), and hospital readmission rates at 30 days and 90 days after
394 hospital discharge. Functional status and quality of life issues are considered part of this
395 evaluation, even beyond the initial 3-month follow-up period, as well as the stepwise evaluation
396 of patients for the development of chronic thromboembolic pulmonary hypertension (CTEPH) or
397 chronic thromboembolic pulmonary disease (CTEPD).²³⁻²⁷

398 Lastly, the data elements include indicators of information having been provided for
399 education of the patient and his/her family, in particular regarding the use of anticoagulant drugs.

400

401 **DISCUSSION**

402 Large gaps in the evidence base regarding management of PE have resulted in substantial
403 variations in care. Identification and capture of appropriate data elements during the journey of
404 the PE patient, from presentation to discharge and into follow-up, will be critical to expansion of
405 the evidence base and represent the first step towards a more pragmatic and evidence-based
406 approach to patient care in this rapidly evolving field. The current document establishes a
407 baseline of relevant data elements, generated by consensus of the Pulmonary Embolism Research
408 Collaborative (PERCTM) in conjunction with FDA, that are appropriate to collect during the PE
409 patient journey. Elements are included on the basis of their known or potential effect on outcome
410 and are designated as either “core” or “enhanced”. The core set represents the minimum
411 necessary elements for capture, while the enhanced set includes additional parameters that may
412 be useful to inform future understanding of PE and influence treatment strategies. Analysis of
413 these data will enlighten the medical community and provide guidance regarding current best
414 practices, and will serve as the foundation for improving therapies moving forward. While
415 establishing a standardized set of data elements was the main objective of the PERCTM, another
416 key objective of the initiative was for the expert collaborators to collectively identify the
417 shortcomings and data gaps in PE care.

418 During the course of the PERCTM deliberations, in addition to identifying specific
419 elements worthy of capture, several important considerations were identified that affect PE data
420 collection. Addressing each of these will be important as part of the effort to expand the PE
421 evidence base and close the knowledge gap regarding optimal management.

422 *Threshold for Activation and Data Capture*

423 The “spectrum of PE”, or the varying degrees in which this disease presents, is an
424 acknowledged phenomenon and is a function of many variables. The threshold for various
425 treatments, based on this spectrum, is not well defined. Similarly, the threshold for full PERT
426 activation is not standardized in regard to this spectrum. Indeed, the significant variations in care
427 were the stimulus for promoting the team-based concept of PE care (PERTs) and are one of the
428 most compelling reasons for collecting and analyzing patterns of PE care in a registry.
429 Acknowledging the variations in presentation and severity of PE, the data elements
430 recommended for capture herein may not be necessary or appropriate for every patient with acute
431 PE.

432

433 *Statistical Analysis*

434 Data acquired through registries and other sources using the PERC template and
435 definitions will be subjected to rigorous review as a part of all subsequent analyses.
436 Missingness, which plagues many registry databases, will be addressed as part of this review.
437 The pragmatism of fully capturing data elements will be affected by many factors, including then
438 number and complexity of the elements identified, the resources available at the point of
439 collection, and the level of ascertainment required by the respective registry or collection tool.
440 The data elements recommended for capture within this document represent a comprehensive list
441 of those that were identified as minimally necessary elements (i.e. core) or those which provide
442 for more detailed analysis or are exploratory regarding their impact on outcome (i.e. enhanced).
443 Both core and enhanced data may be useful to inform future understanding of PE and influence
444 treatment strategies. It is acknowledged that these constitute a long list of elements, which may
445 be challenging to capture fully and comprehensively. It is also understood that, as the list of
446 elements for capture increases, the potential for increase in missing data also exists. Appropriate
447 data ascertainment is important since significant missing data will hinder the data evaluation and
448 analytic process. Thus, the intention of this document is to emphasize capture of the core
449 elements. Data quality and integrity and the value of the subsequent statistical analyses will rely
450 upon identification of the most critical (i.e. essential) elements and sufficient ascertainment
451 thereof.

452

453 *Data Collection Timepoints*

454 The timing and, more importantly, the frequency with which data elements should be
455 captured for input into any registry or clinical trial database is an important consideration. PE
456 patients represent a wide spectrum of severity and, therefore, the level of monitoring and data
457 capture will vary as well. For example, a patient with a recent cardiac arrest would be receiving
458 real-time electronic monitoring with continuous recording of data from oxygen saturation probes,
459 arterial blood pressure recording lines, and respiratory rates. Whereas, a patient who is stable and
460 minimally symptomatic may be admitted to a standard medical floor and only have clinical
461 observations documented every six hours. It would not be appropriate to expect those respective
462 frequencies to be required for capture and, on the other hand, a less rigorous approach might fail

463 to capture important and relevant information. To strike a balance, it was felt that observations
464 on all patients should be recorded and inputted to registries at a minimum of once per day, with
465 more intense requirements for those at the more critical end of the spectrum. Of course, this is
466 conjecture and the ideal timepoints are yet to be understood. An ability to interface national PE
467 registries with electronic medical records (EMR) may be helpful in this respect, as software
468 bridges could be written that allow automated extraction of clinical observations data from the
469 EMR source. This remains to be further explored, as ongoing expansion of the evidence base
470 sheds light on optimal timepoints and intervals for data collection.

471

472 *Use of AI for Data Capture*

473 Artificial Intelligence (AI) is playing an increasingly important role in facilitating the
474 diagnosis and management of acute PE. Machine learning algorithms can expedite and enhance
475 the detection of PE on CT scans, as well as the presence of echocardiographic findings such as
476 RV strain. Further, AI programs can integrate clinical data to define risk scores and facilitate
477 decision-making. Ultimately, AI may not only inform the clinical team and guide management
478 but may also suggest new management paradigms based on input from outcomes combined with
479 computer mediated “deep learning.”

480 Current AI programs access raw data from imaging modalities and subject those data to
481 analysis to define presence of a PE and its characteristics. AI programs are now establishing
482 communication pathways with electronic medical records, allowing for assimilation of patient
483 data (including laboratory values, clinical information, and test results). Integration of these data,
484 when subjected to AI tools such as machine and deep learning, will provide a more
485 comprehensive analysis of patient risk, clinical status, and optimal treatment.

486 AI will be a powerful tool to optimize data capture and provide a more robust evidence
487 base for PE. During the process of accessing and organizing raw data from imaging modalities
488 and the electronic medical record, these programs can be utilized to automatically populate PE
489 databases. By enabling data collection “in the background,” AI will provide more standardization
490 of data collection, reduce subjectivity, ensure more consistency in interpretation, and reduce
491 “missingness” (enhance ascertainment). Beyond this, deep (“cognitive”) learning extrapolated
492 from these data will add a new dimension to the evidence base and ultimately enhance the
493 treatment paradigms for PE, through more accurate calculation of existing risk scores, creation of

494 novel, more comprehensive risk calculators, and establishment of increasingly effective care
495 pathways.

496

497 **Partnership with FDA**

498 FDA has been an active participant in this project and shares common goals of
499 optimizing care, improving outcomes, and ensuring safety and efficacy in the care of PE patients.
500 The challenges facing treating clinicians are similar to the questions that regulatory experts
501 grapple with when evaluating the risk-benefit profile of new PE devices and treatment strategies.
502 FDA is committed to least burdensome approaches²⁸ to marketing applications. Better
503 understanding of decision-making surrounding escalation and use of advance therapies, as well
504 as the relative effectiveness of various treatment strategies in different PE populations, can
505 inform regulatory strategies, potentially streamline the availability of effective new treatments,
506 and foster innovation in the care of the PE patient. Ongoing participation of regulatory agencies
507 in PERC™, coupled with an associated robust registry, provides an opportunity to assist in
508 regulatory decision making. This supports the FDA's priority to advance the use of real-world
509 evidence (RWE)^{29, 30}.

510

511 **CONCLUSION**

512 The PERC™ initiative was designed to identify gaps in the knowledge base regarding
513 care of pulmonary embolism and to establish a standardized set of data elements to collect in
514 patients with PE. Utilization of the elements identified and defined by PERC™ within registries
515 and clinical trials, with appropriate data-sharing arrangements, will enable coalescence of data to
516 perform large-scale analyses that will expand the evidence base for PE and ultimately inform
517 best practices. Engagement of multispecialty physicians, device manufacturers, pharmacological
518 experts, patient advocates, as well as regulatory representatives from both device and drug
519 agencies in the PERC™ process enabled a broad-based understanding of the evidence gaps.
520 PERC™ has set the stage to address these evidence gaps and promote progress in PE care.

521

522 **ACKNOWLEDGEMENTS**

523

524 We would like to acknowledge the contributions from all attendees at the inaugural PERCTM
525 meeting held in Washington DC on April 22, 2022 (**Appendix 2**).

526

527 **SOURCES OF FUNDING**

528 None

529

530 **DISCLOSURES**

531 Submitted separately

532

533 **APPENDICES**

534

535 **Appendix 1 – Core and Enhanced Data Elements for Collection in Acute PE Patients**

536 *See attached Excel spreadsheet*

537 **Appendix 2 - Inaugural PERCTM Meeting Contributors**

538 *See attached Word document*

539

540

541 REFERENCES


- 542 1. Sedhom R, Megaly M, Elbadawi A, Elgendy IY, Witzke CF, Kalra S, et al. Contemporary national
543 trends and outcomes of pulmonary embolism in the united states. *Am J Cardiol.* 2022;176:132-
544 138
- 545 2. Benjamin EJ, Virani SS, Callaway CW, Chamberlain AM, Chang AR, Cheng S, et al. Heart disease
546 and stroke statistics-2018 update: A report from the american heart association. *Circulation.*
547 2018;137:e67-e492
- 548 3. Heit JA, Spencer FA, White RH. The epidemiology of venous thromboembolism. *J Thromb*
549 *Thrombolysis.* 2016;41:3-14
- 550 4. Smith SB, Geske JB, Kathuria P, Cuttica M, Schimmel DR, Courtney DM, et al. Analysis of national
551 trends in admissions for pulmonary embolism. *Chest.* 2016;150:35-45
- 552 5. Barco S, Mahmoudpour SH, Valerio L, Klok FA, Munzel T, Middeldorp S, et al. Trends in mortality
553 related to pulmonary embolism in the european region, 2000-15: Analysis of vital registration
554 data from the who mortality database. *Lancet Respir Med.* 2020;8:277-287
- 555 6. Barco S, Valerio L, Ageno W, Cohen AT, Goldhaber SZ, Hunt BJ, et al. Age-sex specific pulmonary
556 embolism-related mortality in the USA and canada, 2000-18: An analysis of the who mortality
557 database and of the cdc multiple cause of death database. *Lancet Respir Med.* 2021;9:33-42
- 558 7. Huisman MV, Barco S, Cannegieter SC, Le Gal G, Konstantinides SV, Reitsma PH, et al. Pulmonary
559 embolism. *Nat Rev Dis Primers.* 2018;4:18028
- 560 8. Gwozdz AM, de Jong CMM, Fialho LS, Likitabhorn T, Sossi F, Jaber PB, et al. Development of an
561 international standard set of outcome measures for patients with venous thromboembolism: An
562 international consortium for health outcomes measurement consensus recommendation.
563 *Lancet Haematol.* 2022;9:e698-e706
- 564 9. de Jong CMM, Rosovsky RP, Klok FA. Outcomes of venous thromboembolism care: Future
565 directions. *J Thromb Haemost.* 2023;21:1082-1089
- 566 10. U.S. Department of Health and Human Services Office of Minority Health. Homepage. 2022
- 567 11. U.S. Food and Drug Administration Communication. Collection of race and ethnicity data in
568 clinical trials. 2016
- 569 12. Martin KA, McCabe ME, Feinglass J, Khan SS. Racial disparities exist across age groups in illinois
570 for pulmonary embolism hospitalizations. *Arterioscler Thromb Vasc Biol.* 2020;40:2338-2340
- 571 13. Phillips AR, Reitz KM, Myers S, Thoma F, Andraska EA, Jano A, et al. Association between black
572 race, clinical severity, and management of acute pulmonary embolism: A retrospective cohort
573 study. *J Am Heart Assoc.* 2021;10:e021818
- 574 14. Pribish AM, Beyer SE, Krawisz AK, Weinberg I, Carroll BJ, Secemsky EA. Sex differences in
575 presentation, management, and outcomes among patients hospitalized with acute pulmonary
576 embolism. *Vasc Med.* 2020;25:541-548
- 577 15. Agarwal S, Clark D, 3rd, Sud K, Jaber WA, Cho L, Menon V. Gender disparities in outcomes and
578 resource utilization for acute pulmonary embolism hospitalizations in the united states. *Am J*
579 *Cardiol.* 2015;116:1270-1276
- 580 16. Wadhwa RK, Secemsky EA, Wang Y, Yeh RW, Goldhaber SZ. Association of socioeconomic
581 disadvantage with mortality and readmissions among older adults hospitalized for pulmonary
582 embolism in the united states. *J Am Heart Assoc.* 2021;10:e021117
- 583 17. Aujesky D, Obrosky DS, Stone RA, Auble TE, Perrier A, Cornuz J, et al. Derivation and validation
584 of a prognostic model for pulmonary embolism. *Am J Respir Crit Care Med.* 2005;172:1041-1046

- 585 18. Bova C, Sanchez O, Prandoni P, Lankeit M, Konstantinides S, Vanni S, et al. Identification of
586 intermediate-risk patients with acute symptomatic pulmonary embolism. *Eur Respir J.*
587 2014;44:694-703
- 588 19. RCoPo L. National early warning score (news): Standardising the assessment of acute-illness
589 severity in the nhs — report of a working party. *Royal College of Physicians.* 2012
- 590 20. Bavalia R, Stals MAM, Mulder FI, Bistervels IM, Coppens M, Faber LM, et al. Use of the national
591 early warning score for predicting deterioration of patients with acute pulmonary embolism: A
592 post-hoc analysis of the years study. *Emerg Med J.* 2023;40:61-66
- 593 21. Rawal A, Ardeshta D, Hesterberg K, Cave B, Ibebuogu UN, Khouzam RN. Is there an optimal
594 "door to cath time" in the treatment of acute pulmonary embolism with catheter-directed
595 thrombolysis? *Ann Transl Med.* 2019;7:419
- 596 22. Pruszczyk P, Klok FA, Kucher N, Roik M, Meneveau N, Sharp ASP, et al. Percutaneous treatment
597 options for acute pulmonary embolism: A clinical consensus statement by the esc working group
598 on pulmonary circulation and right ventricular function and the european association of
599 percutaneous cardiovascular interventions. *EuroIntervention.* 2022;18:e623-e638
- 600 23. Boon G, Barco S, Bertolotti L, Ghanima W, Huisman MV, Kahn SR, et al. Measuring functional
601 limitations after venous thromboembolism: Optimization of the post-vte functional status (pvfs)
602 scale. *Thrombosis research.* 2020;190:45-51
- 603 24. Klok FA, Cohn DM, Middeldorp S, Scharloo M, Buller HR, van Kralingen KW, et al. Quality of life
604 after pulmonary embolism: Validation of the pemb-qol questionnaire. *J Thromb Haemost.*
605 2010;8:523-532
- 606 25. Delcroix M, Torbicki A, Gopalan D, Sitbon O, Klok FA, Lang I, et al. Ers statement on chronic
607 thromboembolic pulmonary hypertension. *Eur Respir J.* 2021;57
- 608 26. Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, et al. 2022 esc/ers
609 guidelines for the diagnosis and treatment of pulmonary hypertension. *Eur Heart J.*
610 2022;43:3618-3731
- 611 27. Morris TA, Fernandes TM, Channick RN. Evaluation of dyspnea and exercise intolerance after
612 acute pulmonary embolism. *Chest.* 2023;163:933-941
- 613 28. U.S. Food and Drug Administration. The least burdensome provisions: Concept and principles.
614 2019
- 615 29. U.S. Food and Drug Administration. Use of real-world evidence to support regulatory decision-
616 making for medical devices. 2017
- 617 30. U.S. Food and Drug Administration. Real-world data: Assessing registries to support regulatory
618 decision-making for drug and biological products - guidance for industry. 2021
- 619 31. Stein PD, Matta F, Goldman J. Obesity and pulmonary embolism: The mounting evidence of risk
620 and the mortality paradox. *Thrombosis research.* 2011;128:518-523
- 621 32. Gauthier K, Kovacs MJ, Wells PS, Le Gal G, Rodger M, investigators R. Family history of venous
622 thromboembolism (vte) as a predictor for recurrent vte in unprovoked vte patients. *J Thromb*
623 *Haemost.* 2013;11:200-203
- 624 33. Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing GJ, Harjola VP, et al. 2019 esc
625 guidelines for the diagnosis and management of acute pulmonary embolism developed in
626 collaboration with the european respiratory society (ers): The task force for the diagnosis and
627 management of acute pulmonary embolism of the european society of cardiology (esc). *Eur*
628 *Respir J.* 2019;54
- 629 34. Budd AC, Rhodes M, Forster AJ, Noghani P, Carrier M, Wells PS. Prescribing patterns and
630 outcomes of venous thromboembolism prophylaxis in hospitalized medical and cancer patients:
631 Observations from the ottawa hospital. *Thrombosis research.* 2021;197:144-152

- 632 35. Garcia D, Akl EA, Carr R, Kearon C. Antiphospholipid antibodies and the risk of recurrence after a
633 first episode of venous thromboembolism: A systematic review. *Blood*. 2013;122:817-824
- 634 36. Rodger MA, Kahn SR, Wells PS, Anderson DA, Chagnon I, Le Gal G, et al. Identifying unprovoked
635 thromboembolism patients at low risk for recurrence who can discontinue anticoagulant
636 therapy. *CMAJ*. 2008;179:417-426
- 637 37. de Winter MA, van Es N, Buller HR, Visseren FLJ, Nijkeuter M. Prediction models for recurrence
638 and bleeding in patients with venous thromboembolism: A systematic review and critical
639 appraisal. *Thrombosis research*. 2021;199:85-96
- 640 38. Prins MH, Lensing AWA, Prandoni P, Wells PS, Verhamme P, Beyer-Westendorf J, et al. Risk of
641 recurrent venous thromboembolism according to baseline risk factor profiles. *Blood Adv*.
642 2018;2:788-796
- 643 39. Bates SM, Ginsberg JS. Clinical practice. Treatment of deep-vein thrombosis. *N Engl J Med*.
644 2004;351:268-277
- 645 40. Rosano GMC, Rodriguez-Martinez MA, Spoletini I, Regidor PA. Obesity and contraceptive use:
646 Impact on cardiovascular risk. *ESC Heart Fail*. 2022
- 647 41. Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the S, Standardization
648 Committee of the International Society on T, Haemostasis. Definition of major bleeding in
649 clinical investigations of antihemostatic medicinal products in non-surgical patients. *J Thromb*
650 *Haemost*. 2005;3:692-694
- 651 42. Quigley N, Gagnon S, Fortin M. Aetiology, diagnosis and treatment of moderate-to-severe
652 haemoptysis in a north american academic centre. *ERJ Open Res*. 2020;6
- 653 43. Meyer G, Vicaut E, Danays T, Agnelli G, Becattini C, Beyer-Westendorf J, et al. Fibrinolysis for
654 patients with intermediate-risk pulmonary embolism. *N Engl J Med*. 2014;370:1402-1411
- 655 44. The Joint Commission. National patient safety goal for anticoagulant therapy. 2018:1-4
- 656 45. Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing GJ, Harjola VP, et al. 2019 esc
657 guidelines for the diagnosis and management of acute pulmonary embolism developed in
658 collaboration with the european respiratory society (ers). *Eur Heart J*. 2020;41:543-603
- 659 46. Gaddh M, Rosovsky RP. Venous thromboembolism: Genetics and thrombophilias. *Semin Respir*
660 *Crit Care Med*. 2021;42:271-283
- 661 47. Khair RM, Nwaneri C, Damico RL, Kolb T, Hassoun PM, Mathai SC. The minimal important
662 difference in borg dyspnea score in pulmonary arterial hypertension. *Ann Am Thorac Soc*.
663 2016;13:842-849
664
665

666

Figure 1: Multi-Disciplinary Experts contributing to Inaugural PERC™ Meeting



667

668

669



670

Figure 2: Data Element Collection throughout the 5 stages of the PE journey

671

672

673

674

Table 1: Overview of critical gaps in evidence per stage of the PE journey

Initial assessment and acute treatment
1. What are, at initial assessment, the most relevant comorbidities, demographic parameters (including socioeconomic status), presenting symptoms, clinical signs, and (imaging) biomarkers for optimal risk stratification of acute PE? What combination of parameters should be utilized to produce the “ideal risk score”?
2. What is the potential value/contribution of Artificial Intelligence (AI) in a) facilitating/accelerating diagnosis of PE, b) determining risk, c) coordinating care?
3. What are the various institutional approaches to PE? Is there multidisciplinary involvement? In which institutions are there formal teams (e.g., PERTs) and for which patients is that team involved? What is the influence, value, advantages, and disadvantages of the PERT approach?
4. When is primary reperfusion therapy for acute PE indicated?
Interventional management, acute outcomes and adverse events
5. What are the therapeutic outcomes (technical, procedural, and clinical success), safety profile, and complications associated with (the combination of) various interventional and pharmacologic management strategies for PE?
6. What is the role of ECMO and other hemodynamic support (e.g., Veno-veno bypass and RV support systems) in the treatment of patients with acute PE?
7. How is treatment success of the different management strategies for PE defined?
Hospital monitoring post-intervention
8. How (which clinical/biomarker/imaging parameters to measure, which scores to use), how often, and where should patients optimally be monitored during initial hospitalization and treatment? What combination of parameters should be utilized to produce the “ideal risk score”?
9. Where (department, type of hospital) are PE patients optimally managed?
10. Which parameters are appropriate to evaluate/measure prior to discharge and what values must be achieved to ensure safe discharge?

Post discharge management
11. What are the intermediate and long-term effects and outcomes of acute PE, and its treatment strategy, with respect to clinical complications, functional status, and quality of life?
12. What constitutes appropriate and optimal follow up care for patients with acute PE, including timing of reassessments and relevant parameters to measure? How might utilization of standardized follow-up algorithms influence management?

675

676

677

Table 2: Definition of treatment success

Acute Outcome	Definition
Device success	Successful delivery of the device without device deficiency to the pulmonary artery, with subsequent function per IFU
Technical success	Successful delivery of designed intervention, whether evidence of successful thrombus removal or delivery of thrombolytic, in the absence of device deficiency
Procedural success	Both technical and clinical success are achieved
Acute clinical success-hemodynamically stable patients	Improvement within 48 hours of a therapeutic procedure including: 1) clinical improvement in vital signs (reduced O2 requirements without ambulation and/or improved HR), 2) symptomatic improvement (PR), 3) invasive physiologic improvement, 4) non-invasive imaging improvement
Acute clinical success-hemodynamically unstable patients	Improvement in hemodynamics within 48 hrs of a therapeutic procedure including resolution of unstable physiology as defined by one or more of the following: 1) resolution of hypotension, 2) removal of vasoactive drugs, 3) extubation, 4) decannulation from MCS

678

679

680 **Table 3:** Definition of treatment failure and complications of treatment

Adverse Event	Definition
Major bleeding	ISTH definition

Hemoptysis	If a patient coughs up blood with sputum or has frank bleeding into the airway. If present, classify into moderate or major
Moderate hemoptysis	Less than 50 mL of blood without the need for additional intervention
Major hemoptysis	Greater than 50 mL of blood with or without additional intervention
Impending respiratory arrest	A patient with intact neurologic function becomes agitated, confused and struggles to breathe. Usually associated with tachycardia, diaphoresis and intercostal or sternoclavicular retractions
Device malfunction	Failure of a medical device to perform in accordance with its intended purpose when used in accordance with the instructions for use
Device user error	User action or lack of user action while using the medical device that leads to a different result than that intended by the manufacturer or expected by the user
Device Inadequacy of IFU	Insufficient or misleading information in the instructions for use or labeling
Device fracture/component separation	Undesirable damage to a medical device involving the loss of structural integrity, such as a partial or full thickness crack in the device materials, or loss of adherence between device materials, resulting in an undesirable separation, breaking apart, or detachment of some part or piece(s) of the device
Access site complication	Any persistent bleeding or hematoma in conjunction with the need for transfusion, or access-site vascular injury requiring intervention (e.g. surgical or endovascular repair)
Clinical deterioration	Defined as one in the following: 1) need for cardiopulmonary resuscitation, 2) systolic blood pressure < 90 mm Hg for at least 15 min, 3) drop in systolic blood pressure by at least 40 mm Hg for at least 15 minutes with signs of end-organ

	hypoperfusion (cold extremities or low urinary output < 30 mL/h or mental confusion), 4) need for catecholamine administration to maintain adequate organ perfusion and a systolic blood pressure of > 90 mm Hg (including dopamine at the rate of > 5 microgram/kg per minute), 5) unplanned endotracheal intubation, 6) unexpected requirement for mechanical ventilation, 7) emergency surgical embolectomy
Device-related death at 48 hours	Death directly related to the device, including from the following: 1) vascular or cardiovascular injury, 2) device malfunction, 3) device-induced cardiac arrhythmia, 4) worsening pulmonary or right heart function (exclusive of worsening from recurrent PE)